AnaptysBio (NASDAQ:ANAB) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of AnaptysBio (NASDAQ:ANAB) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

Several other equities analysts also recently issued reports on ANAB. Jefferies Financial Group downgraded AnaptysBio from a buy rating to a hold rating and set a $12.00 target price on the stock. in a research report on Friday, November 8th. ValuEngine raised AnaptysBio from a hold rating to a buy rating in a research report on Friday, August 16th. Credit Suisse Group cut their target price on AnaptysBio from $75.00 to $48.00 and set a neutral rating on the stock in a research report on Thursday, October 3rd. SunTrust Banks downgraded AnaptysBio from a buy rating to a hold rating in a research report on Friday, November 8th. Finally, JPMorgan Chase & Co. downgraded AnaptysBio from an overweight rating to an underweight rating and cut their price target for the stock from $109.00 to $17.00 in a research report on Friday, November 8th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $75.11.

Shares of NASDAQ ANAB traded up $0.21 during trading hours on Wednesday, reaching $11.10. The stock had a trading volume of 973,300 shares, compared to its average volume of 1,635,621. The business’s fifty day moving average price is $32.62 and its two-hundred day moving average price is $51.41. AnaptysBio has a 52-week low of $10.00 and a 52-week high of $83.10. The firm has a market cap of $295.48 million, a price-to-earnings ratio of -4.44 and a beta of 1.50.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Friday, November 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.06). During the same quarter in the previous year, the business earned ($0.66) earnings per share. As a group, equities research analysts anticipate that AnaptysBio will post -4.01 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in ANAB. Amundi Pioneer Asset Management Inc. acquired a new stake in AnaptysBio during the 1st quarter worth about $110,000. Whittier Trust Co. acquired a new stake in AnaptysBio during the 2nd quarter worth about $213,000. Quantitative Systematic Strategies LLC acquired a new stake in AnaptysBio during the 2nd quarter worth about $258,000. Los Angeles Capital Management & Equity Research Inc. grew its position in AnaptysBio by 15.1% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 12,470 shares of the biotechnology company’s stock worth $704,000 after purchasing an additional 1,635 shares during the period. Finally, Janney Montgomery Scott LLC grew its position in AnaptysBio by 6.3% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,226 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 251 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Further Reading: What is meant by a buy rating?

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.